Research progress of DprE1 inhibitors as new anti-tuberculosis drugs
Li Lu, Tang Shenjie
Clinical Medicine Center, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China
Abstract：Tuberculosis continues to be one of the most serious infectious diseases threatening human health. At the moment, clinical use of antituberculosis drugs has a poor therapeutic effect, has a high cost, has side effects, and has other flaws. As a result, there is an urgent need to develop new antitubercular drugs with new mechanism of action that are safer, more widely effective, and less toxic. Some progress has been made in the study of DprE1 inhibitors′ antituberculosis effect in recent years. DprE1 inhibitors target the cell wall of mycobacterium tuberculosis and inhibit its growth by inhibiting the DprE1 enzyme that produces the mycobacterium tuberculosis cell wall.This paper reviewed DprE1 inhibitors interms of classification, mechanism of action, antimicrobial activity, pharmacokinetics and pharmacodynamics, as well as drug safety, animal experiments, and clinical trials.
李璐 唐神结. DprE1抑制剂抗结核新药研究进展[J]. 中华诊断学电子杂志, 2022, 10(3): 207-210.
Li Lu, Tang Shenjie. Research progress of DprE1 inhibitors as new anti-tuberculosis drugs. zhzdx, 2022, 10(3): 207-210.
